CHRISTIE BALLANTYNE to 1-Alkyl-2-acetylglycerophosphocholine Esterase
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about 1-Alkyl-2-acetylglycerophosphocholine Esterase.
Connection Strength
2.293
-
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC). Atherosclerosis. 2018 01; 268:12-18.
Score: 0.570
-
Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009 Feb; 40(2):376-81.
Score: 0.307
-
ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
Score: 0.158
-
Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 05 01; 121(9):1056-1064.
Score: 0.145
-
Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts. Am Heart J. 2018 03; 197:62-69.
Score: 0.143
-
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis. 2015 Aug; 241(2):641-8.
Score: 0.121
-
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
Score: 0.113
-
Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study. Thromb Res. 2013 Jul; 132(1):44-6.
Score: 0.105
-
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc. 2013 Jun; 45(6):1043-50.
Score: 0.105
-
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 01; 375(9725):1536-44.
Score: 0.084
-
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
Score: 0.074
-
How to identify patients with vulnerable plaques. Diabetes Obes Metab. 2008 Sep; 10(10):824-33.
Score: 0.071
-
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005 Nov 28; 165(21):2479-84.
Score: 0.062
-
PLAC test for identification of individuals at increased risk for coronary heart disease. Expert Rev Mol Diagn. 2005 Jan; 5(1):9-14.
Score: 0.058
-
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1?, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022 08 02; 146(5):372-379.
Score: 0.049
-
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). Am J Cardiol. 2017 Feb 01; 119(3):397-403.
Score: 0.033
-
Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
Score: 0.033
-
Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J. 2012 Jan; 33(2):238-51.
Score: 0.023
-
Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
Score: 0.023
-
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006 Jul 10; 166(13):1368-73.
Score: 0.016